Several biomarker studies using human CSF demonstrate that ratios comprising Aβ42/total-tau and Aβ42/phospho-tau may accurately indicate transition from normal to mild cognitive impairment, and full AD onset [243–245], reiterating the importance of both markers in AD diagnosis. The gene discussed is MAPT; the disease is Cognitive impairment.